Local Clinic Offers Newly Approved Monotherapy Option for Treatment-Resistant Depression – No Daily Antidepressant Required
San Luis Obispo, Ca / Access Newswire / November 16, 2025 / Innerbloom Ketamine Therapy announces the addition of SPRAVATO® (esketamine) nasal spray to its comprehensive mental health treatment offerings, providing San Luis Obispo residents access to an FDA-approved treatment for treatment-resistant depression that can now be used with or without a daily oral antidepressant.
Earlier this year, SPRAVATO® received FDA approval as the first and only medication for treating treatment-resistant depression without requiring a daily oral antidepressant-a significant advancement for patients who haven’t found relief with conventional treatments or cannot tolerate them.
The Innerbloom clinic, founded by board-certified trauma surgeon Dr. Ray Rivas in 2022, already specializes in IV and intramuscular ketamine therapy for depression, anxiety, PTSD, and chronic pain. The addition of SPRAVATO® monotherapy represents the clinic’s commitment to offering the most advanced, evidence-based options available.
“We’ve witnessed the transformative power of ketamine therapy in our community over the past three years,” said Dr. Rivas, who brings over 12 years of ketamine administration experience from his background in trauma surgery. “This new FDA approval is remarkable-patients can now experience the benefits of SPRAVATO® as a standalone treatment, with relief possible within 24 hours and without the need for daily oral medications that many have struggled with.”
SPRAVATO® is specifically indicated for adults with treatment-resistant depression-defined as depression that persists despite trying at least two different antidepressant medications. Clinical trials demonstrated that 22.5% of patients taking SPRAVATO® achieved remission at week four, compared to just 7.6% taking placebo. Patients experienced rapid and superior improvement in depressive symptoms as early as 24 hours, a dramatic contrast to the typical 4-6 week wait for traditional antidepressants to take effect.
The self-administered nasal spray is used under strict medical supervision in the clinic, with patients monitored for at least two hours following each treatment. SPRAVATO® works by targeting glutamate, the most abundant excitatory neurotransmitter in the brain, through a mechanism distinct from traditional antidepressants.
“The setting matters as much as the treatment itself,” noted Dr. Rivas. “Our patients receive SPRAVATO® in a calm, beautiful environment designed specifically for healing, with continuous support from our care team throughout the entire process.”
